CTLA-4 in regulatory T cells for cancer immunotherapy N Sobhani, DR Tardiel-Cyril, A Davtyan, D Generali, R Roudi, Y Li Cancers 13 (6), 1440, 2021 | 170 | 2021 |
Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer N Sobhani, A D’Angelo, M Pittacolo, G Roviello, A Miccoli, SP Corona, ... Cells 8 (4), 321, 2019 | 132 | 2019 |
The prognostic value of PI3K mutational status in breast cancer: A meta‐analysis N Sobhani, G Roviello, SP Corona, M Scaltriti, A Ianza, M Bortul, ... Journal of cellular biochemistry 119 (6), 4287-4292, 2018 | 108 | 2018 |
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies GR Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta ... Cancers 12 (11), E3293, 2020 | 62 | 2020 |
The fibroblast growth factor receptors in breast cancer: from oncogenesis to better treatments N Sobhani, C Fan, P O. Flores-Villanueva, D Generali, Y Li International journal of molecular sciences 21 (6), 2011, 2020 | 61 | 2020 |
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials N Sobhani, B Scaggiante, R Morris, D Chai, M Catalano, DR Tardiel-Cyril, ... Cancer treatment reviews 109, 102429, 2022 | 47 | 2022 |
Advances in systemic therapy for metastatic breast cancer: future perspectives SP Corona, N Sobhani, A Ianza, G Roviello, G Mustacchi, M Bortul, ... Medical oncology 34, 1-16, 2017 | 47 | 2017 |
Cancer/testis antigens: from serology to mRNA cancer vaccine C Fan, H Qu, X Wang, N Sobhani, L Wang, S Liu, W Xiong, Z Zeng, Y Li Seminars in cancer biology 76, 218-231, 2021 | 42 | 2021 |
Current status of fibroblast growth factor receptor-targeted therapies in breast cancer N Sobhani, A Ianza, A D’angelo, G Roviello, F Giudici, M Bortul, ... Cells 7 (7), 76, 2018 | 42 | 2018 |
Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer N Sobhani, A Fassl, G Mondani, D Generali, T Otto Cells 10 (2), 293, 2021 | 37 | 2021 |
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? N Sobhani, D Generali, F Zanconati, M Bortul, B Scaggiante World journal of clinical oncology 9 (2), 26, 2018 | 37 | 2018 |
AR-V7 in metastatic prostate cancer: a strategy beyond redemption N Sobhani, PK Neeli, A D’angelo, M Pittacolo, M Sirico, IC Galli, ... International journal of molecular sciences 22 (11), 5515, 2021 | 34 | 2021 |
Advances in anti-BRAF therapies for lung cancer G Roviello, A D’Angelo, M Sirico, M Pittacolo, FU Conter, N Sobhani Investigational New Drugs 39 (3), 879-890, 2021 | 33 | 2021 |
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma A D’Angelo, N Sobhani, G Roviello, S Bagby, D Bonazza, C Bottin, ... PLoS One 14 (8), e0219566, 2019 | 33 | 2019 |
Lenvatinib for the treatment of renal cell carcinoma G Roviello, SP Corona, G Bozza, M Aieta, D Generali, MG Rodriquenz, ... Expert Opinion on Investigational Drugs 27 (5), 507-512, 2018 | 24 | 2018 |
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer N Sobhani, D Generali, A D’Angelo, M Aieta, G Roviello Investigational new drugs 36 (6), 1133-1137, 2018 | 23 | 2018 |
Mutant p53 as an antigen in cancer immunotherapy N Sobhani, A D’angelo, X Wang, KH Young, D Generali, Y Li International journal of molecular sciences 21 (11), 4087, 2020 | 22 | 2020 |
Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects R Roudi, A D'Angelo, M Sirico, N Sobhani International Immunopharmacology 101, 108322, 2021 | 21 | 2021 |
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer G Roviello, FU Conter, E Mini, D Generali, M Traversini, D Lavacchi, ... Cancer chemotherapy and pharmacology 84, 669-677, 2019 | 21 | 2019 |
Avelumab in gastric cancer G Roviello, A D’Angelo, D Generali, M Pittacolo, M Ganzinelli, G Iezzi, ... Immunotherapy 11 (9), 759-768, 2019 | 20 | 2019 |